State of New Jersey Common Pension Fund D Acquires 22,893 Shares of ADMA Biologics Inc $ADMA

Key Points

• The State of New Jersey Common Pension Fund D increased its stake in ADMA Biologics Inc by 22.5% during the first quarter, owning approximately $2.47 million worth of shares.
• Insiders at ADMA Biologics have recently sold a significant amount of shares, with one director selling 10,000 shares for about $213,100, representing a 2.05% decrease in their ownership.
• ADMA Biologics reported a quarterly earnings per share of $0.15, beating analysts' estimates, while quarterly revenue increased by 13.8% year-over-year.

State of New Jersey Common Pension Fund D increased its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 22.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 124,646 shares of the biotechnology company's stock after purchasing an additional 22,893 shares during the period. State of New Jersey Common Pension Fund D owned approximately 0.05% of ADMA Biologics worth $2,473,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. New York State Teachers Retirement System increased its holdings in shares of ADMA Biologics by 96.2% in the 1st quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock worth $4,402,000 after buying an additional 108,800 shares during the last quarter. GAMMA Investing LLC increased its stake in ADMA Biologics by 251.6% in the first quarter. GAMMA Investing LLC now owns 6,589 shares of the biotechnology company's stock valued at $131,000 after acquiring an additional 4,715 shares during the last quarter. Concurrent Investment Advisors LLC bought a new stake in ADMA Biologics during the first quarter worth about $201,000. Ameriprise Financial Inc. lifted its stake in ADMA Biologics by 14.1% during the fourth quarter. Ameriprise Financial Inc. now owns 715,672 shares of the biotechnology company's stock worth $12,274,000 after purchasing an additional 88,542 shares during the last quarter. Finally, Penserra Capital Management LLC bought a new position in shares of ADMA Biologics during the 1st quarter valued at about $2,293,000. 75.68% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the transaction, the director directly owned 94,830 shares in the company, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director directly owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 455,621 shares of company stock worth $9,461,633. 3.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have issued reports on ADMA. Raymond James Financial upped their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to data from MarketBeat, ADMA Biologics currently has a consensus rating of "Buy" and a consensus price target of $27.67.

ADMA Biologics Trading Up 0.2%

Shares of NASDAQ:ADMA traded up $0.04 during trading on Tuesday, reaching $17.05. 864,213 shares of the company traded hands, compared to its average volume of 3,107,244. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a 52-week low of $13.50 and a 52-week high of $25.67. The firm has a market capitalization of $4.07 billion, a price-to-earnings ratio of 19.82 and a beta of 0.38. The business's fifty day moving average is $17.84 and its 200-day moving average is $18.90.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. The firm had revenue of $121.98 million for the quarter, compared to analysts' expectations of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company's revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.13 earnings per share. As a group, analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.